Duration of Ceftazidime and Aztreonam Therapy Based on Culture Results
General Duration Guidelines
- For most bacterial infections, treatment with ceftazidime and aztreonam should be administered for 7-14 days, with treatment continued for at least 48 hours after the patient becomes asymptomatic or evidence of bacterial eradication has been obtained 1
- For mild to moderate infections, a 5-7 day course is generally safe and effective when patients achieve clinical stability 1
- For severe or life-threatening infections, a minimum of 7-14 days of therapy is recommended 1
- Clinical improvement should be evident within 48-72 hours of initiating appropriate therapy 1
- Premature discontinuation of therapy before clinical stability is achieved should be avoided 1
Duration by Infection Type
- For bloodstream infections: 7-14 days 2
- For complicated urinary tract infections: 5-7 days 2
- For hospital-acquired or ventilator-associated pneumonia: 10-14 days 2
Special Considerations for Carbapenem-Resistant Infections
- For metallo-β-lactamase-producing CRE infections, ceftazidime-avibactam combined with aztreonam is recommended as the preferred treatment option 3, 4
- This combination has shown significantly lower 30-day mortality (19.2% vs 44%) compared to other antimicrobial therapies 3, 2
- The carbapenemase type produced by CRE strains should be ascertained before initiation of ceftazidime-avibactam treatment whenever possible 3
Dosing Considerations
- Standard dosing for ceftazidime-avibactam is 2.5 g IV every 8 hours administered as a 2-hour infusion 2
- Standard aztreonam dosing is 2 g IV every 8 hours 2
Important Caveats
- Acinetobacter species demonstrate intrinsic resistance to ceftazidime-avibactam due to OXA-type carbapenemases not inhibited by avibactam 5
- For CRAB (Carbapenem-Resistant Acinetobacter baumannii) infections, tigecycline-based or polymyxin-based combination therapies are preferred 3, 5
- Emergence of ceftazidime-avibactam resistance in carbapenemase-producing K. pneumoniae has been reported, particularly with prior administration of the drug 2
- Immunocompromised patients may require longer treatment courses 1
Aztreonam Treatment Guidelines for Metallo-β-Lactamase-Producing Organisms
Special Considerations for Metallo-β-Lactamase-Producing Carbapenem-Resistant Organisms
- Aztreonam is uniquely active against metallo-β-lactamase (MBL)-producing carbapenem-resistant Enterobacteriaceae (CRE), as recommended by the Infectious Diseases Society of America 6
- For hospital-acquired pneumonia where MRSA coverage is not used but aztreonam is chosen due to penicillin allergy, additional coverage for methicillin-sensitive Staphylococcus aureus (MSSA) should be included, according to the Infectious Diseases Society of America 7